Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome - PubMed (original) (raw)
Randomized Controlled Trial
. 2017 Aug;153(2):448-459.e8.
doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5.
Geoffrey B Hall 2, Kathy Ghajar 2, Andrea Nardelli 1, Carolina Bolino 1, Jennifer T Lau 1, Francois-Pierre Martin 3, Ornella Cominetti 3, Christopher Welsh 1, Amber Rieder 2, Jenna Traynor 2, Caitlin Gregory 2, Giada De Palma 1, Marc Pigrau 1, Alexander C Ford 4, Joseph Macri 5, Bernard Berger 6, Gabriela Bergonzelli 6, Michael G Surette 1, Stephen M Collins 1, Paul Moayyedi 1, Premysl Bercik 7
Affiliations
- PMID: 28483500
- DOI: 10.1053/j.gastro.2017.05.003
Free article
Randomized Controlled Trial
Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome
Maria Ines Pinto-Sanchez et al. Gastroenterology. 2017 Aug.
Free article
Abstract
Background & aims: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known about their effects on psychiatric comorbidities. We performed a prospective study to evaluate the effects of Bifidobacterium longum NCC3001 (BL) on anxiety and depression in patients with IBS.
Methods: We performed a randomized, double-blind, placebo-controlled study of 44 adults with IBS and diarrhea or a mixed-stool pattern (based on Rome III criteria) and mild to moderate anxiety and/or depression (based on the Hospital Anxiety and Depression scale) at McMaster University in Canada, from March 2011 to May 2014. At the screening visit, clinical history and symptoms were assessed and blood samples were collected. Patients were then randomly assigned to groups and given daily BL (n = 22) or placebo (n = 22) for 6 weeks. At weeks 0, 6, and 10, we determined patients' levels of anxiety and depression, IBS symptoms, quality of life, and somatization using validated questionnaires. At weeks 0 and 6, stool, urine and blood samples were collected, and functional magnetic resonance imaging (fMRI) test was performed. We assessed brain activation patterns, fecal microbiota, urine metabolome profiles, serum markers of inflammation, neurotransmitters, and neurotrophin levels.
Results: At week 6, 14 of 22 patients in the BL group had reduction in depression scores of 2 points or more on the Hospital Anxiety and Depression scale, vs 7 of 22 patients in the placebo group (P = .04). BL had no significant effect on anxiety or IBS symptoms. Patients in the BL group had a mean increase in quality of life score compared with the placebo group. The fMRI analysis showed that BL reduced responses to negative emotional stimuli in multiple brain areas, including amygdala and fronto-limbic regions, compared with placebo. The groups had similar fecal microbiota profiles, serum markers of inflammation, and levels of neurotrophins and neurotransmitters, but the BL group had reduced urine levels of methylamines and aromatic amino acids metabolites. At week 10, depression scores were reduced in patients given BL vs placebo.
Conclusion: In a placebo-controlled trial, we found that the probiotic BL reduces depression but not anxiety scores and increases quality of life in patients with IBS. These improvements were associated with changes in brain activation patterns that indicate that this probiotic reduces limbic reactivity. ClinicalTrials.gov no. NCT01276626.
Keywords: Anxiety; Depression; IBS; fMRI.
Copyright © 2017. Published by Elsevier Inc.
Comment in
- IBS: Mindful of probiotics for psychiatric comorbidities in IBS.
Ray K. Ray K. Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):386-387. doi: 10.1038/nrgastro.2017.70. Epub 2017 May 24. Nat Rev Gastroenterol Hepatol. 2017. PMID: 28536484 No abstract available. - Reply.
Pinto Sanchez MI, Moayyedi P, Bercik P. Pinto Sanchez MI, et al. Gastroenterology. 2018 Feb;154(3):764-765. doi: 10.1053/j.gastro.2018.01.022. Epub 2018 Jan 17. Gastroenterology. 2018. PMID: 29351832 No abstract available. - Endoscopy Examination Time: Longer Is Really Better?
Lo GH. Lo GH. Gastroenterology. 2018 Feb;154(3):765. doi: 10.1053/j.gastro.2017.09.056. Epub 2018 Jan 18. Gastroenterology. 2018. PMID: 29352955 No abstract available. - The Fragility of Probiotic Bifidobacterium longum NCC3001 Use for Depression in Patients With Irritable Bowel Syndrome.
Meyer C, Vassar M. Meyer C, et al. Gastroenterology. 2018 Feb;154(3):764. doi: 10.1053/j.gastro.2017.09.055. Epub 2018 Jan 17. Gastroenterology. 2018. PMID: 29352957 No abstract available.
Similar articles
- Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic.
Martin FP, Cominetti O, Berger B, Combremont S, Marquis J, Xie G, Jia W, Pinto-Sanchez MI, Bercik P, Bergonzelli G. Martin FP, et al. Gut Microbes. 2024 Jan-Dec;16(1):2347715. doi: 10.1080/19490976.2024.2347715. Epub 2024 May 8. Gut Microbes. 2024. PMID: 38717445 Free PMC article. Clinical Trial. - The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. Ki Cha B, et al. J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1. J Clin Gastroenterol. 2012. PMID: 22157240 Clinical Trial. - Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study.
Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, Evans M. Lewis ED, et al. Nutrients. 2020 Apr 21;12(4):1159. doi: 10.3390/nu12041159. Nutrients. 2020. PMID: 32326347 Free PMC article. Clinical Trial. - Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Yuan F, et al. Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7. Curr Med Res Opin. 2017. PMID: 28166427 Review. - Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
Didari T, Mozaffari S, Nikfar S, Abdollahi M. Didari T, et al. World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072. World J Gastroenterol. 2015. PMID: 25780308 Free PMC article. Review.
Cited by
- Interaction of the gut microbiota and brain functional connectivity in late-life depression.
Tsai CF, Chuang CH, Tu PC, Chang WC, Wang YP, Liu PY, Wu PS, Lin CY, Lu CL. Tsai CF, et al. J Psychiatry Neurosci. 2024 Sep 19;49(5):E289-E300. doi: 10.1503/jpn.240050. Print 2024 Sep-Oct. J Psychiatry Neurosci. 2024. PMID: 39299780 Free PMC article. - Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review.
Iribarren C, Maasfeh L, Öhman L, Simrén M. Iribarren C, et al. Gut Microbiome (Camb). 2022 Aug 25;3:e7. doi: 10.1017/gmb.2022.6. eCollection 2022. Gut Microbiome (Camb). 2022. PMID: 39295774 Free PMC article. Review. - Gut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders.
Verma A, Inslicht SS, Bhargava A. Verma A, et al. Cells. 2024 Aug 27;13(17):1436. doi: 10.3390/cells13171436. Cells. 2024. PMID: 39273008 Free PMC article. Review. - Probiotics and Fecal Microbiota Transplantation in Major Depression: Doxa or Episteme?
Evrensel A. Evrensel A. Adv Exp Med Biol. 2024;1456:67-83. doi: 10.1007/978-981-97-4402-2_4. Adv Exp Med Biol. 2024. PMID: 39261424 Review. - Exploring the Potential of Probiotics and Prebiotics in Major Depression: From Molecular Function to Clinical Therapy.
Yuan X, Chai J, Xu W, Zhao Y. Yuan X, et al. Probiotics Antimicrob Proteins. 2024 Jul 30. doi: 10.1007/s12602-024-10326-z. Online ahead of print. Probiotics Antimicrob Proteins. 2024. PMID: 39078446 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical